NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free ME Stock Alerts $0.40 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.39▼$0.4150-Day Range$0.36▼$0.6152-Week Range$0.35▼$2.03Volume3.06 million shsAverage Volume6.34 million shsMarket Capitalization$196.10 millionP/E RatioN/ADividend YieldN/APrice Target$0.47 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get 23andMe alerts: Email Address 23andMe MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside17.5% Upside$0.47 Price TargetShort InterestBearish12.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 2 Articles This WeekInsider TradingSelling Shares$74,014 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.36 out of 5 starsMedical Sector879th out of 913 stocksPharmaceutical Preparations Industry414th out of 429 stocks 2.0 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst Coverage23andMe has only been the subject of 1 research reports in the past 90 days.Read more about 23andMe's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.89% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in 23andMe has recently decreased by 3.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 1.2 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 23andMe this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for ME on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,014.00 in company stock.Percentage Held by Insiders27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.10% of the stock of 23andMe is held by institutions.Read more about 23andMe's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 23andMe's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About 23andMe Stock (NASDAQ:ME)23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Read More ME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ME Stock News HeadlinesJune 11, 2024 | investorplace.com3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June EditionJune 10, 2024 | reuters.comCanada, UK launched joint probe into 23andMe data breach, says CanadaJune 5, 2024 | globenewswire.com23andMe Launches New Genetic Report on Bipolar DisorderJune 4, 2024 | fool.comWhy 23andMe Stock Tumbled 10% on TuesdayJune 3, 2024 | globenewswire.com23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual MeetingMay 29, 2024 | globenewswire.comLargest study on the LRRK2 variant leads to discoveries about health, ancestry, and historyMay 28, 2024 | msn.comAtlanta soldier finally found and buried after going missing during World War IIMay 25, 2024 | finance.yahoo.com23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 24, 2024 | msn.com23andMe Holding Co. (NASDAQ:ME) Q4 2024 Earnings Call TranscriptMay 24, 2024 | finance.yahoo.comQ4 2024 23andMe Holding Co. Earnings CallMay 24, 2024 | finanznachrichten.de23andMe, Inc.: 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsMay 24, 2024 | markets.businessinsider.com23andMe Holding (ME) Buy Rating Justified by Strong Revenue and Strategic DevelopmentsMay 23, 2024 | investorplace.comME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024May 23, 2024 | globenewswire.com23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsMay 20, 2024 | msn.comThis Nevada pageant queen was abandoned as a baby. Now she’s reunited with her birth motherMay 20, 2024 | msn.comThis pageant queen was abandoned as a baby. Now, she’s reunited with her birth mother.May 17, 2024 | msn.comDid 23andMe Sell Genetic Data to Chinese Government?May 16, 2024 | yahoo.comFact Check: About That Claim 23andMe Sold Genetic Data to Chinese GovernmentMay 14, 2024 | msn.comChrissy Teigen Explains Why She Briefly Thought She Had an Identical TwinMay 14, 2024 | globenewswire.comLemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsMay 10, 2024 | finance.yahoo.comStruggling 23andMe Granted Extension to Revive Stock PriceMay 9, 2024 | globenewswire.com23andMe to Report Q4 and Full Year FY2024 Financial ResultsMay 9, 2024 | msn.comAncestryDNA, 23andMe introduce you to new relatives. Now the nightmare: They won't offer medical history.May 7, 2024 | msn.comFind your family tree without compromising your dataMay 7, 2024 | yahoo.comThe 23andMe DNA test makes the most thoughtful Mother's Day surprise, and right now it's less than $150 — save 35%See More Headlines Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/23/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees769Year FoundedN/APrice Target and Rating Average Stock Price Target$0.47 High Stock Price Target$0.47 Low Stock Price Target$0.47 Potential Upside/Downside+17.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-666,700,000.00 Net Margins-303.55% Pretax Margin-303.51% Return on Equity-66.15% Return on Assets-46.14% Debt Debt-to-Equity RatioN/A Current Ratio2.01 Quick Ratio1.91 Sales & Book Value Annual Sales$219.64 million Price / Sales0.89 Cash Flow$0.15 per share Price / Cash Flow2.68 Book Value$0.38 per share Price / Book1.05Miscellaneous Outstanding Shares490,260,000Free Float355,191,000Market Cap$196.10 million OptionableNot Optionable Beta1.27 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMs. Anne WojcickiCo-Founder, CEO, President & Chair of the BoardMr. Joseph Selsavage (Age 61)Interim CFO & Accounting Officer Comp: $574.56kMr. Eli FryVice President of OperationsMr. Guy ChayounVP, Interim General Counsel & Corporate SecretaryMs. Katie Watson (Age 46)Vice President of Communications Mr. Jonathan WardChief Marketing OfficerMr. Reza Afkhami M.B.A.Chief Corporate Development OfficerMs. Savita PillaiVice President of PeopleDr. Jennifer Low (Age 55)Head of Therapeutics Development Mr. Kent Hillyer (Age 56)Vice President of Consumer Operations More ExecutivesKey CompetitorsBeauty HealthNASDAQ:SKINVoltaNYSE:VLTAEmbark TechnologyNASDAQ:EMBKOppFiNYSE:OPFIHolleyNYSE:HLLYView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 6,242,157 shares on 5/10/2024Ownership: 3.378%SG Americas Securities LLCSold 98,564 shares on 5/7/2024Ownership: 0.024%Wittenberg Investment Management Inc.Bought 893,552 shares on 5/3/2024Ownership: 0.474%Kathy L HibbsSold 38,551 sharesTotal: $18,889.99 ($0.49/share)China Universal Asset Management Co. Ltd.Bought 24,604 shares on 4/29/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ME Stock Analysis - Frequently Asked Questions Should I buy or sell 23andMe stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ME, but not buy additional shares or sell existing shares. View ME analyst ratings or view top-rated stocks. What is 23andMe's stock price target for 2024? 1 equities research analysts have issued 1-year price targets for 23andMe's shares. Their ME share price targets range from $0.47 to $0.47. On average, they expect the company's stock price to reach $0.47 in the next year. This suggests a possible upside of 17.5% from the stock's current price. View analysts price targets for ME or view top-rated stocks among Wall Street analysts. How have ME shares performed in 2024? 23andMe's stock was trading at $0.9135 on January 1st, 2024. Since then, ME stock has decreased by 56.2% and is now trading at $0.40. View the best growth stocks for 2024 here. When is 23andMe's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ME earnings forecast. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings data on Thursday, May, 23rd. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $64.03 million for the quarter, compared to analysts' expectations of $61.90 million. 23andMe had a negative net margin of 303.55% and a negative trailing twelve-month return on equity of 66.15%. Who are 23andMe's major shareholders? 23andMe's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.38%), Wittenberg Investment Management Inc. (0.47%), Mirador Capital Partners LP (0.07%), SG Americas Securities LLC (0.02%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards. View institutional ownership trends. How do I buy shares of 23andMe? Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ME) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredRevealed: The Unknown Biotech Powering AI in HealthcareThe CEO of Google predicted this is "one of the most important things for humanity." We're standing at the ...Behind the Markets | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.